

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claims 1 – 94 cancel

Claim 95. (currently amended) A method to aid in predicting susceptibility of a human subject to development of an estrogen hormone responsive cancer in a mucosal epithelial tissue, the method comprising:

quantitating the level of secreted dimeric/polymeric IgA, polymeric IgM and IgG1 in a secreted body fluid obtained from the subject suspected of comprising a cancer, wherein a level of secreted dimeric/polymeric IgA, polymeric IgM and IgG1 in a secreted body fluid that is lower than wild-type levels, wherein a lower level of secretion is predictive of increased susceptibility of the human to development of the estrogen hormone responsive cancer in a mucosal epithelium, wherein the secreted dimeric/polymeric IgA, polymeric IgM and IgG1 is active for inhibiting proliferation of a steroid hormone responsive cancer cell maintained in a suitable nutrient medium under cell growth promoting conditions, in the absence of an inhibition-reversing amount of the steroid hormone.